吉祥坊登录

On October 17, 2022, the groundbreaking ceremony for the Global Headquarters and the Innovation & Industrialization Base Project of Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”, stock code: 688016.SH) was successfully held in Shanghai International Medical Zone (SIMZ), Zhangjiang Science City, Pudong District of Shanghai. 

Among those witnessing this significant moment were Mr. Peng Bo, chief marketing officer of MicroPort®, chairman of the Greater China Executive Committee of MicroPort®, and chairman of Endovastec™; Dr. Zhu Qing, president of Endovastec™; and other employee representatives of Endovastec™.

The project is located in Block 34B-01 of SIMZ, with a total floor area of 140,000 square meters. Upon completion, it will become an industrial park of Endovastec™ integrating multiple functions such as R&D, testing, manufacturing, offices, and services, with a view to meeting the business development needs of large-scale production in the future. In accordance with the industrial development requirements of SIMZ and relying on the innovation advantages of Endovastec™ developed over the years, the project strives to stand a significant pioneering role in the company’s scientific and technological innovation and develop into a modern benchmark base for manufacturing innovation.

In his speech at the ceremony, President Zhu Qing expressed his gratitude for the strong support from local government and all walks of life as well as the efforts of the project team. “Today’s groundbreaking ceremony marks another important milestone in the innovation and development of Endovastec™. Since its inception, Endovastec™ has seen rapid development through continuous innovation and become a leader in the field of aortic and peripheral vascular interventional medical devices in China. It was among the first companies listed on the STAR Market in 2019, and the fast growth since then has enabled us to speed up the implementation of our conglomerate-style development and global development strategies,” said President Zhu Qing, “Through this project, we will further optimize our product strategies, scale up industrialization, and strengthen our comprehensive competitiveness, thereby laying the foundation for the long-term high-quality growth of the company.”

As a leader in the field of aortic and peripheral vascular interventional medical devices in China, Endovastec™ currently has already launched 13 products, five of which have obtained CE marking. Among the products already launched and under development, seven  have been approved to go through the national “Special Review Procedures for Innovative Medical Devices”, outperforming most other companies in the industry. Products of Endovastec™ have been available in over 1,400 hospitals across China and saved lives of more than 120,000 patients.

Besides, Endovastec™ will develop in the form of a conglomerate to gradually improve the product line layout in the field of peripheral vascular intervention and tumor intervention, continuously optimize the product layout, enhance the competitiveness of the products in the market, and continue production capacity expansion, striving to create the next pole of growth. The company now has various peripheral vascular intervention and tumor intervention products under research and development, and it is expected that they will be rolled out and put into production in the near future to meet the growing market demand at home and abroad.

The products of Endovastec™ have been sold in 22 countries and regions in Europe, Latin America, Southeast Asia, among others. In order to further expand the presence of its innovative products in the international market and accelerate its development globally, the company has been actively setting up R&D centers and sales networks overseas and allocating relevant resources to expedite the drawing of a blueprint for global strategy. At present, the establishment of the North American R&D Center, the European R&D Center and other overseas subsidiaries is well underway.

With a Blueprint in Mind, Bring a Brighter Future for Mankind. The project will lay a solid foundation and make good preparations for Endovastec™ to take off higher and farther. In the future, Endovastec™ will forge ahead with innovations to fulfil its mission of “providing trustworthy and universal access to state-of-the-art total treatment solutions to vascular circulatory diseases”. We are determined to develop the company into a people-centered global leader in new and high medical technologies, making outstanding contributions to the development of the biomedical industry and bringing benefits to patients with circulatory diseases worldwide.